跳至主要内容
临床试验/EUCTR2017-002843-14-DK
EUCTR2017-002843-14-DK进行中(未招募)1 期

Investigations of local skin reactions and safety after combined treatment of basal cell carcinoma using ablative fractional laser and ingenol mebutate - an exloratory, prospective, open-label phase 2a trial.

Bispebjerg Hospital0 个研究点目标入组 30 人开始时间: 2017年7月21日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients with histologically verified, lwo-risk previously untreated superficial or nodular BCCs
  • >18 years old
  • Legally competent, able to give verbal and written consent
  • Subejcts in good general Health, who is willing to participate and able to give informed consent and can comply with protocol requirements
  • Female subjects of childbearing potential must be confirmed not pregnant by a negative urine pregnancy test prior to trial treatment.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 30

排除标准

  • High risk BCC
  • Medical history of Gorlin syndrome or immunosuprresive medication
  • Known allergy to Picato or carboxy fluorescein
  • History of keloids
  • Lactating or pregnant women

研究者

相似试验